Alzheimer's Fast Track 2026
Join us for Alzheimer’s Fast Track, November 11-13, 2026, in Washington, D.C.
Registration opens June 8th!
About Alzheimer’s Fast Track
Learn from experts in the field of Alzheimer’s disease and related dementias at the Alzheimer’s Fast Track workshop. Designed for graduate students, postdoctoral fellows, and other early-career scientists focused on Alzheimer’s disease research, this immersive learning experience will accelerate your knowledge, expertise, and visibility in this exciting field.
2026 Event Details
November 11-13, 2026
Hilton Washington DC National Mall The Wharf
Washington, DC
Official pre-meeting to Society for Neuroscience
Contact researchgrants@brightfocus.org with questions.
Registration opens June 8th, 2026
What Attendees Are Saying
I cannot believe how much this BrightFocus Fast Track has shaped my knowledge, my career and me personally. I also made friends forever. Not only I am so much more prepared and more confident to write grants but also I gained skills to communicate and to share my science. This workshop is the greatest idea to help students build their careers more successfully. Every scientist should go through a workshop like this one. Thank you for the opportunity!
Amira Latif-Hernandez, PhD, Alzheimer’s Disease Research Grant Recipient and Fast Track Attendee
The BrightFocus team shows genuine care for their fellows and their individual career paths, which was evident during the Fast Track event. The opportunity to easily connect with mentors and receive personalized advice truly stood out.
Julie Ottoy, PhD, Alzheimer’s Disease Research Grant Recipient and Fast Track Attendee
Co-Chairs
Frank LaFerla, PhD
University of California, Irvine
Cynthia Lemere, PhD
Brigham and Women’s Hospital, Harvard Medical School
Sharyn Rossi, PhD
BrightFocus Foundation
Harry Steinbusch, PhD
Maastricht University,
The Netherlands
Related News & Research Breakthroughs
Article
Can Better Sleep Slow Alzheimer's?
New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way.
Article
FDA Approves Repurposed Anti-Depressant to Treat Alzheimer's-Associated Agitation
Auvelity, developed by Axsome Therapeutics, was approved today by the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease agitation, a common and challenging symptom that affects 40 to 60 percent of people living with Alzheimer’s.
Article
Breaking News Dispatch: Alzheimer's Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge
Get the latest research news from the 2026 International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference.
Article
Can Targeting the Immune System Slow the Progression of Alzheimer's?
BrightFocus Alzheimer’s Disease Research grant recipient Joshua Emmerson, PhD, is exploring a certain type of immune cell’s unexpected role in Alzheimer’s disease—and what it could mean for protecting the brain.
Article
Unlocking the Brain's Regenerative Potential to Fight Alzheimer's
María Llorens-Martín is investigating why the brain stops making new cells in Alzheimer’s—and how fixing that process could change lives.
Article
Breaking News Dispatch: New Findings on GLP-1 Drugs and Alzheimer's, Novel Treatments in Development, and More
Get the latest news from the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference.